A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1
125
about 3.4 years
18+
13 sites in CA, FL, GA +8
About this study
Researchers are testing a new drug called KTX-1001 to see if it's safe for people with multiple myeloma that has returned or not responded to other treatments. The trial will involve different groups of patients receiving varying combinations of the drug, including KTX-1001 alone and in combination with other medications like mezigdomide, carfilzomib, or pomalidomide.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cohort A1 & A2: KTX-1001
- 2.Take Cohort B1 & B2: KTX-1001+Mezigdomide
- 3.Take Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
carfilzomib, pomalidomide
injection (Injection), oral (Oral Capsule)
Primary: Dose Escalation: Determination of Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose (MTD) Dose Expansion: Provide preliminary efficacy data on the antitumor effects of KTX-1001 in combination with other anti-myeloma therapy
Secondary: Pharmacokinetics & Pharmacodynamics KTX-1001± Combination Therapy
Oncology